pharmaceuticals and medicines for the treatment of cystic fibrosis, pain, sickle cell disease, beta thalassemia, muscular dystrophy, diabetes, respira Read More

Classification Information

Class [005]
Pharmaceuticals and medicines for the treatment of cystic fibrosis, pain, sickle cell disease, beta thalassemia, muscular dystrophy, diabetes, respiratory diseases, liver disease, kidney disease, alpha-1 antitrypsin deficiency and APOL1-mediated kidney disease.

Classification kind code

Mark Details

Serial Number

2318364

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 257 on 28^th Mar 2024	Designation Notification - Madrid Protocol
Submitted for opposition 1 on 28^th Mar 2024	Created
Submitted for opposition 31 on 28^th Mar 2024	Formalized
Submitted for opposition 228 on 26^th Jan 2024	International Registration
Submitted for opposition 30 on 26^th Jan 2024	Filed

REKAYA

Classification Information

Class [005]Pharmaceuticals and medicines for the treatment of cystic fibrosis, pain, sickle cell disease, beta thalassemia, muscular dystrophy, diabetes, respiratory diseases, liver disease, kidney disease, alpha-1 antitrypsin deficiency and APOL1-mediated kidney disease.

Classification kind code

Mark Details

Serial Number

Mark Type

Legal History

Class [005]
Pharmaceuticals and medicines for the treatment of cystic fibrosis, pain, sickle cell disease, beta thalassemia, muscular dystrophy, diabetes, respiratory diseases, liver disease, kidney disease, alpha-1 antitrypsin deficiency and APOL1-mediated kidney disease.